Artelo Biosciences, Inc. (ARTL)
NASDAQ: ARTL · Real-Time Price · USD
10.20
-1.66 (-14.00%)
At close: Aug 1, 2025, 4:00 PM
10.60
+0.40 (3.92%)
After-hours: Aug 1, 2025, 7:59 PM EDT

Company Description

Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, develops and commercializes therapeutics that target lipid-signaling pathways in the United States.

The company’s product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated/ weight loss with cancer; and ART12.11, a synthetic cannabidiol cocrystal for the treatment anxiety, depression, post-traumatic stress disorder PTSD, epilepsy and insomnia, pain and inflammation, and other potential indications.

It also offers ART26.12, a fatty acid binding protein 5 inhibitor for treating chemotherapy induced peripheral neuropathy, diabetic neuropathy, prostate cancer and breast cancer, pain, dermatologic conditions, and anxiety disorders.

The company was formerly known as Reactive Medical Inc. and changed its name to Artelo Biosciences, Inc. in April 2017.

Artelo Biosciences, Inc. was incorporated in 2011 and is based in Solana Beach, California.

Artelo Biosciences, Inc.
Artelo Biosciences logo
CountryUnited States
Founded2011
IndustryBiotechnology
SectorHealthcare
Employees6
CEOGregory Gorgas

Contact Details

Address:
505 Lomas Santa Fe, Suite 160
Solana Beach, California 92075
United States
Phone858 925 7049
Websiteartelobio.com

Stock Details

Ticker SymbolARTL
ExchangeNASDAQ
Stock TypeCommon Stock
Fiscal YearJanuary - December
Reporting CurrencyUSD
CIK Code0001621221
CUSIP Number04301G607
ISIN NumberUS04301G6070
Employer ID33-1220924
SIC Code2834

Key Executives

NamePosition
Gregory D. Gorgas M.B.A.President, Chief Executive Officer, Treasurer, Secretary and Director
Mark E. SpringChief Financial Officer
Dr. Andrew Yates Ph.D.Senior Vice President and Chief Scientific Officer
Dr. Steven D. Reich M.D.Chief Medical Officer
Jason H. BaybuttSenior Vice President of Finance

Latest SEC Filings

DateTypeTitle
Jul 28, 2025PRE 14AOther preliminary proxy statements
Jul 18, 20258-KCurrent Report
Jul 18, 2025424B5Filing
Jul 17, 2025EFFECTNotice of Effectiveness
Jul 11, 2025S-1General form for registration of securities under the Securities Act of 1933
Jul 11, 20258-KCurrent Report
Jul 9, 2025DNotice of Exempt Offering of Securities
Jun 26, 20258-KCurrent Report
Jun 13, 20258-KCurrent Report
May 23, 20258-KCurrent Report